Method for Preparing Targeted Dermal Papilla Cell-Derived Exosomes, Exosome Product, Liquid Hair Growth Formulation
Summary
US Patent Application US20260108562A1, filed October 7, 2025 and published April 23, 2026, discloses a method for preparing targeted exosomes from dermal papilla cells (DPCs) isolated using cell surface marker CD133 from hair follicles of healthy donors in a xeno-free and serum-free environment, with exosomes possessing surface markers CD9, CD63, and CD81 isolated via tangential flow filtration or size exclusion chromatography. The application also covers a liquid hair growth formulation incorporating the resulting lyophilized exosome product. This represents an early-stage intellectual property filing in the hair growth and exosome therapeutics space with no compliance obligations currently in effect.
“A method for preparing targeted dermal papilla cell-derived exosomes is provided.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO Patent Application US20260108562A1 discloses a method for isolating dermal papilla cells using CD133 cell surface markers from healthy donor hair follicles in a xeno-free, serum-free environment, followed by collection of exosomes with CD9, CD63, and CD81 surface markers from culture medium, with isolation via tangential flow filtration or size exclusion chromatography to produce a lyophilized targeted exosome product. A liquid hair growth formulation incorporating this exosome product is also disclosed.
For biotechnology and pharmaceutical companies developing hair growth or exosome-based therapeutics, this application represents potential prior art in the exosome isolation and dermatology space. Competitors pursuing similar DPC-derived exosome approaches should conduct freedom-to-operate analyses and monitor this application's prosecution for potential claim scope that could affect product development strategies.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Method for Preparing Targeted Dermal Papilla Cell-Derived Exosomes, Exosome Product, Liquid Hair Growth Formulation, and Method of Using Liquid Hair Growth Formulation
Application US20260108562A1 Kind: A1 Apr 23, 2026
Inventors
Chun-Chou Tsai
Abstract
A method for preparing targeted dermal papilla cell-derived exosomes is provided. The method involves first isolating a plurality of dermal papilla cells (DPCs) with a cell surface marker CD133 from the hair follicles of a healthy donor, in a xeno-free and serum-free environment in GTP lab in Taiwan (or GMP lab in international). Subsequently, a cell culture medium containing a plurality of exosomes is collected, wherein these exosomes possess surface markers such as CD9, CD63, and CD81. Finally, the exosomes are isolated, concentrated, and purified from the culture medium using techniques such as tangential flow filtration system (TFF system) or size exclusion chromatography, thereby obtaining the final targeted exosome lyophilized product. A liquid hair growth formulation formulated with this exosome product is also provided.
CPC Classifications
A61K 35/36 A61P 17/14 C12N 5/0627
Filing Date
2025-10-07
Application No.
19352402
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.